scholarly journals Severe Symptomatic Hyponatremia Secondary to Escitalopram-Induced SIADH: A Case Report with Literature Review

2018 ◽  
Vol 2018 ◽  
pp. 1-7
Author(s):  
Rishi Raj ◽  
Aasems Jacob ◽  
Ajay Venkatanarayan ◽  
Mohankumar Doraiswamy ◽  
Manjula Ashok

Hyponatremia is a well-known medication related side effect of selective serotonin reuptake inhibitors; despite its association with escitalopram, the newest SSRI is very rare. We did a review of literature and came across only 14 reported case of this rare association of SIADH with escitalopram. We hereby report a case of a 93-year-old female who presented with generalized tonic-clonic seizure and was diagnosed with severe hyponatremia due to escitalopram-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH). With this article, we want to emphasize clinicians about this rare side effect of escitalopram use and look for the risk factors leading to SIADH.

2019 ◽  
Vol 2 (6) ◽  
pp. 327-329
Author(s):  
Koki Maeda ◽  
Susumu Kageyama ◽  
Takashi Osafune ◽  
Yoshikata Masuda ◽  
Shota Nakagawa ◽  
...  

1998 ◽  
Vol 32 (1) ◽  
pp. 49-51 ◽  
Author(s):  
Gule Rana Masood ◽  
Shyam D Karki ◽  
William R Patterson

OBJECTIVE To describe a patient with hyponatremia associated with venlafaxine therapy. CASE SUMMARY: A 92-year-old white woman who was receiving venlafaxine for management of depression was found to have hyponatremia. A detailed workup confirmed the diagnosis of syndrome of inappropriate antidiuretic hormone secretion (SIADH). A temporal relationship between initiation of venlafaxine therapy and the onset of hyponatremia indicated it as the probable cause. Venlafaxine was discontinued, and hyponatremia resolved within a few weeks. DISCUSSION: Hyponatremia has been reported with selective serotonin-reuptake inhibitors (SSRIs). Serotonin has been reported to elevate concentrations of vasopressin in animal models. Venlafaxine is a potent inhibitor of serotonin reuptake and may have adverse effects similar to those of SSRIs. CONCLUSIONS We report a case of hyponatremia probably caused by venlafaxine. Awareness of this potential problem would be helpful to clinicians and should be considered in the differential diagnosis of hyponatremia. OBJETIVO Informar el caso de un paciente con hiponatremia asociada al tratamiento con venlafaxine. RESUMEN Una mujer de 92 años en tratamiento con venlafaxine para el manejo de depresión desarrolló hiponatremia. Sus otros medicamentos concurrentes incluían fenobarbital 120 mg al acostarse, enalapril 10 mg/d, furosemida 20 mg/d, carbonato de calcio 650 mg dos veces al día, y nortriptilina 50 mg al acostarse. Una evaluación detallada confirmó el diagnóstico del síndrome inadecuado de la hormona antidiurética. La relación temporal entre el inicio del tratamiento con venlafaxine y el inicio de la hiponatremia tiende a señalar a este medicamento como el causante. Al descontinuar el venlafaxine la hiponatremia se resolvió en unas pocas semanas. DISCUSIÓN La hiponatremia ha sido asociada con los inhibidores selectivos de la recaptación de serotonina (ISRS). En modelos de animales se ha demostrado que la serotonina eleva los niveles de vasopresina. Venlafaxine es un inhibidor potente de la recaptación de serotonina y puede tener efectos adversos similares a los de los ISRS. CONCLUSIONES: Se informó un caso de hiponatremia probablemente causada por venlafaxine. Desde que se sometió este informe han sido publicados tres informes similares de hiponatremia atribuídos a este antidepresivo. Esto sugiere que venlafaxine puede causar hiponatremia. vasopresina. Venlafaxine es un inhibidor potente de la recaptación de serotonina y puede tener efectos adversos similares a los de los ISRS. CONCLUSIONES: Se informó un caso de hiponatremia probablemente causada por venlafaxine. Desde que se sometió este informe han sido publicados tres informes similares de hiponatremia atribuídos a este antidepresivo. Esto sugiere que venlafaxine puede causar hiponatremia. Este hecho debe ser considerado al hacer el diagnóstico diferencial de cualquier paciente que desarrolle hiponatremia mientras esté utilizando este medicamento. Este hecho debe ser considerado al hacer el diagnóstico diferencial de cualquier paciente que desarrolle hiponatremia mientras esté utilizando este medicamento.


2016 ◽  
Vol 2016 ◽  
pp. 1-4 ◽  
Author(s):  
Mihaela Mocan ◽  
Sorin Nicu Blaga

Hyponatremia (serum Na levels of <135 mEq/L) is the most common electrolyte imbalance encountered in clinical practice, affecting up to 15–28% of hospitalized patients. This case report refers to a middle-aged man with severe hyponatremia due to Syndrome of Inappropriate Antidiuretic Hormone Secretion related to four possible etiological factors: glossopharyngeal squamous cell carcinoma, cisplatin treatment, right basal pneumonia with Pseudomonas aeruginosa, and the treatment with Levofloxacin. This case report discusses a rare complication of common conditions and of a common treatment. To our knowledge this is the first case of hyponatremia related to Levofloxacin and the second related to fluoroquinolones.


2010 ◽  
Vol 20 (6) ◽  
pp. 277-278 ◽  
Author(s):  
Aydin Unal ◽  
Ismail Kocyigit ◽  
Murat Hayri Sipahioglu ◽  
Bulent Tokgoz ◽  
Oktay Oymak ◽  
...  

Author(s):  
Ahmed Osman Saleh ◽  
Shaikha D. Al-Shokri ◽  
Ashraf Ahmed ◽  
Ahmed Elmustafa Musa ◽  
Mouhand FH Mohamed

Coronavirus disease 2019 (COVID-19) was first reported in Wuhan, China, in December 2019. The disease is caused by severe acute respiratory syndrome virus coronavirus 2 (SARS-CoV-2). A few published cases have linked COVID-19 and hyponatremia. The mechanism of hyponatremia in these cases is related to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Here we present a unique case of urinary retention and SIADH as unusual presenting features of SARS-CoV-2 infection.


Sign in / Sign up

Export Citation Format

Share Document